Establishment of biomarkers to predict response to glucocorticoids for thyroid eye disease by DIA proteome analysis.

The standard treatment for thyroid eye disease is glucocorticoid administration, however its response varies from case to case. In recent years, treatment of thyroid eye disease has evolved dramatically, and the efficacy of several agents is being demonstrated. If steroid resistance is identified prior to treatment, the quality of care can be improved by using other agents as first-line therapy. We performed DIA proteome analysis on pretreatment sera of glucocorticoids response and resistance patients to search for candidate biomarkers of therapeutic response. Sera from healthy subjects and those with Graves' disease without thyroid eye disease are also analyzed together as controls.